73
Participants
Start Date
October 8, 2024
Primary Completion Date
September 17, 2025
Study Completion Date
September 17, 2025
Remdesivir
"Remdesivir is a prodrug that is intended to allow intracellular delivery of GS-441524 monophosphate and subsequent biotransformation into GS-441524 triphosphate, a ribonucleotide analogue inhibitor of viral RNA polymerase.~Participants will receive a single loading dose of 200 milligrams of Remdesivir in 250ml sodium chloride 0.9% bag via IV over 60 minutes on day 1, followed by, on days 2 - 5, a dose of 100 milligrams of Remdesivir in 250ml sodium chloride 0.9% bag via IV once daily over 30 minutes."
University of Derby, Derby
Derbyshire Community Health Services NHS Foundation Trust, Chesterfield
Royal Derby Hospital (UHDB), Derby
University of Exeter / Royal Devon University Healthcare NHS FT, Exeter
University of Exeter
OTHER
University of Plymouth
OTHER
University Hospitals of Derby and Burton NHS Foundation Trust
OTHER
Aston University
OTHER
Royal Devon and Exeter NHS Foundation Trust
OTHER
University of Derby
OTHER